ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

In Congress: HHS Funding Bill Vetoed, Congress, White House Negotiating on Budget

November 12, 1999

Anil Potti Explains: “Coming from India, I Did Not Know This Was Not The Real Rhodes Scholarship”

December 16, 2011

ACCC To Present Program On Impact Of New Technology

January 23, 1981

In Brief: Elion, Schein, Johnson Head Societies; Phillips, Salmon Elected; McIntire, Pistenma to Leave NCI

June 3, 1983

Reports On AACR Scientific Sessions

May 21, 1976

Centers Subcommittee Kills Guidelines Proposal, Suggest Formula Ceiling On Core Grants

January 6, 1978